AFSTYLAAntihemophilic Factor (Recombinant), Single Chain (CSL Behring Recombinant facility AG)
Welcome to the PulseAid listing for the AFSTYLA drug offered from CSL Behring Recombinant facility AG. This pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.
LABELER NAME / MANUFACTURER: | CSL Behring Recombinant facility AG |
NON-PROPRIETARY NAME: | ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT |
SUBSTANCE NAME: | |
TYPE: | PLASMA DERIVATIVE |
PHARMA CLASS: | |
ROUTE: | |
DOSAGE FORM: | KIT |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2016-05-25 |
END MARKETING DATE: | 0000-00-00 |
AFSTYLA Antihemophilic Factor (Recombinant), Single Chain PLASMA DERIVATIVE Details:
Item Description | AFSTYLA Antihemophilic Factor (Recombinant), Single Chain from CSL Behring Recombinant facility AG |
LABELER NAME: | CSL Behring Recombinant facility AG |
DEA SCHEDULE: | |
ACTIVE STRENGTH: | () |
START MARKETING DATE: | 2016-05-25 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 69911-474_caf84084-b71d-483b-a0be-24e66a6a21bc |
PRODUCT NDC: | 69911-474 |
APPLICATION NUMBER: | BLA125591 |